Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Higher-Risk Myelodysplastic Syndrome: A Phase 1b StudyJacqueline S. Garcia, Guillermo Garcia‐Manero, Leah J. Hogdal et al.|Blood|2020Cited by 58
Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-ThalassemiaKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|Blood|2021Cited by 7
P112: ENERGIZE AND ENERGIZE-T: TWO PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDIES OF MITAPIVAT IN ADULTS WITH NON--TRANSFUSION-DEPENDENT OR TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIAKevin H.M. Kuo, Maria Domenica Cappellini, D. Mark Layton et al.|HemaSphere|2022Cited by 6
Mitapivat Improves Markers of Erythropoietic Activity in Long-Term Study of Adults with Alpha- or Beta-Non-Transfusion-Dependent ThalassemiaKevin H.M. Kuo, Elliott Vichinsky, D. Mark Layton et al.|Blood|2022Cited by 6
Durable Clinical Benefits with Exagamglogene Autotemcel for Transfusion-Dependent β-ThalassemiaFranco Locatelli, Haydar Frangoul, Peter Lang et al.|Blood|2024Cited by 4